TY - JOUR
T1 - The path towards consensus genome classification of diffuse large B-cell lymphoma for use in clinical practice
AU - Mendeville, Matias
AU - Roemer, Margaretha G. M.
AU - Los-de Vries, G. Tjitske
AU - Chamuleau, Martine E. D.
AU - de Jong, Daphne
AU - Ylstra, Bauke
N1 - Funding Information: This work was supported by the Dutch Cancer Society grant KWF 2012-5711. Publisher Copyright: Copyright © 2022 Mendeville, Roemer, Los-de Vries, Chamuleau, de Jong and Ylstra.
PY - 2022/10/27
Y1 - 2022/10/27
N2 - Diffuse large B-cell lymphoma (DLBCL) is a widely heterogeneous disease in presentation, treatment response and outcome that results from a broad biological heterogeneity. Various stratification approaches have been proposed over time but failed to sufficiently capture the heterogeneous biology and behavior of the disease in a clinically relevant manner. The most recent DNA-based genomic subtyping studies are a major step forward by offering a level of refinement that could serve as a basis for exploration of personalized and targeted treatment for the years to come. To enable consistent trial designs and allow meaningful comparisons between studies, harmonization of the currently available knowledge into a single genomic classification widely applicable in daily practice is pivotal. In this review, we investigate potential avenues for harmonization of the presently available genomic subtypes of DLBCL inspired by consensus molecular classifications achieved for other malignancies. Finally, suggestions for laboratory techniques and infrastructure required for successful clinical implementation are described.
AB - Diffuse large B-cell lymphoma (DLBCL) is a widely heterogeneous disease in presentation, treatment response and outcome that results from a broad biological heterogeneity. Various stratification approaches have been proposed over time but failed to sufficiently capture the heterogeneous biology and behavior of the disease in a clinically relevant manner. The most recent DNA-based genomic subtyping studies are a major step forward by offering a level of refinement that could serve as a basis for exploration of personalized and targeted treatment for the years to come. To enable consistent trial designs and allow meaningful comparisons between studies, harmonization of the currently available knowledge into a single genomic classification widely applicable in daily practice is pivotal. In this review, we investigate potential avenues for harmonization of the presently available genomic subtypes of DLBCL inspired by consensus molecular classifications achieved for other malignancies. Finally, suggestions for laboratory techniques and infrastructure required for successful clinical implementation are described.
KW - bioinformatics
KW - consensus classification
KW - diffuse large B-cell lymphoma (DLBCL)
KW - genomics
KW - next generation sequencing (NGS)
UR - http://www.scopus.com/inward/record.url?scp=85141705442&partnerID=8YFLogxK
U2 - https://doi.org/10.3389/fonc.2022.970063
DO - https://doi.org/10.3389/fonc.2022.970063
M3 - Review article
C2 - 36387143
SN - 2234-943X
VL - 12
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 970063
ER -